BR112014006473A2 - composição e método para tratamento de uma doença autoimune - Google Patents

composição e método para tratamento de uma doença autoimune

Info

Publication number
BR112014006473A2
BR112014006473A2 BR112014006473A BR112014006473A BR112014006473A2 BR 112014006473 A2 BR112014006473 A2 BR 112014006473A2 BR 112014006473 A BR112014006473 A BR 112014006473A BR 112014006473 A BR112014006473 A BR 112014006473A BR 112014006473 A2 BR112014006473 A2 BR 112014006473A2
Authority
BR
Brazil
Prior art keywords
autoimmune disease
treating
composition
clofazimine
clarithromycin
Prior art date
Application number
BR112014006473A
Other languages
English (en)
Inventor
Jefferson Leighton Harry
Laughlin Mclean Patrick
Fathi Reza
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47914967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014006473(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of BR112014006473A2 publication Critical patent/BR112014006473A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5929,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "composição e método para tratamento de uma doença autoimune". a presente invenção refere-se a uma combinação de antibióticos incluindo rifabutina, claritromicina, e clofazimina, para o tratamento de uma doença autoimune, tais como esclerose múltipla e doenças relacionadas.
BR112014006473A 2011-09-20 2012-09-19 composição e método para tratamento de uma doença autoimune BR112014006473A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161536824P 2011-09-20 2011-09-20
US201161537229P 2011-09-21 2011-09-21
PCT/IB2012/002252 WO2013041963A2 (en) 2011-09-20 2012-09-19 A composition and method for treating an autoimmune disease

Publications (1)

Publication Number Publication Date
BR112014006473A2 true BR112014006473A2 (pt) 2017-03-28

Family

ID=47914967

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006473A BR112014006473A2 (pt) 2011-09-20 2012-09-19 composição e método para tratamento de uma doença autoimune

Country Status (22)

Country Link
US (1) US9901638B2 (pt)
EP (1) EP2758061B1 (pt)
JP (1) JP6035340B2 (pt)
KR (1) KR101987512B1 (pt)
CN (1) CN103813797B (pt)
AU (1) AU2012311235B2 (pt)
BR (1) BR112014006473A2 (pt)
CA (1) CA2849255C (pt)
CL (1) CL2014000671A1 (pt)
DK (1) DK2758061T3 (pt)
ES (1) ES2614923T3 (pt)
HU (1) HUE032959T2 (pt)
IL (1) IL231489A (pt)
IN (1) IN2014CN02908A (pt)
MX (1) MX347660B (pt)
PL (1) PL2758061T3 (pt)
PT (1) PT2758061T (pt)
RU (1) RU2621129C2 (pt)
SG (1) SG11201400386RA (pt)
TW (1) TWI573590B (pt)
WO (1) WO2013041963A2 (pt)
ZA (1) ZA201401954B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014262125B2 (en) * 2013-04-30 2020-02-13 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
US20150335672A1 (en) 2014-05-22 2015-11-26 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Antibiotics
EP3359255A4 (en) * 2015-10-06 2019-06-12 Redhill Biopharma Ltd. POLYTHERAPIES FOR THE TREATMENT OF CANCER
UA124148C2 (uk) 2016-05-02 2021-07-28 Протена Біосайенсіс Лімітед Антитіла, що розпізнають тау
MX2020002659A (es) 2017-09-08 2020-09-09 Evelo Biosciences Inc Vesiculas extracelulares bacterianas.
AU2021298936A1 (en) * 2020-06-30 2023-01-19 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
WO2023182288A1 (ja) * 2022-03-22 2023-09-28 国立大学法人京都大学 シャルコー・マリー・ツース病の治療または予防薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524951A (ja) * 1997-04-01 2001-12-04 トーマス ジュリアス ボロディー 炎症性腸疾患を治療するための方法および組成物
US7488580B1 (en) 2005-03-10 2009-02-10 University Of Central Florida Research Foundation, Inc. Protocol for detection of Mycobacterium avium subspecies paratuberculosis in blood
US20090054380A1 (en) * 2005-12-20 2009-02-26 Greenstein Robert J Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection
US20080275063A1 (en) 2007-04-24 2008-11-06 Heike Schauerte Inhibitors of protein kinases
EP2200613B1 (en) * 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
DK2247291T3 (en) 2008-02-08 2019-01-21 Red Hill Biopharma Ltd Methods and compositions for treating inflammatory bowel disease
WO2011011706A2 (en) * 2009-07-24 2011-01-27 The Johns Hopkins University Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents

Also Published As

Publication number Publication date
JP6035340B2 (ja) 2016-11-30
TWI573590B (zh) 2017-03-11
MX347660B (es) 2017-05-08
WO2013041963A2 (en) 2013-03-28
AU2012311235A1 (en) 2014-03-20
US20140228307A1 (en) 2014-08-14
CN103813797A (zh) 2014-05-21
SG11201400386RA (en) 2014-09-26
EP2758061A4 (en) 2015-02-25
TW201320999A (zh) 2013-06-01
HUE032959T2 (hu) 2017-11-28
PT2758061T (pt) 2017-02-14
WO2013041963A3 (en) 2013-06-06
CA2849255A1 (en) 2013-03-28
IN2014CN02908A (pt) 2015-07-03
CL2014000671A1 (es) 2014-10-03
KR20140082982A (ko) 2014-07-03
DK2758061T3 (en) 2017-02-20
MX2014003430A (es) 2014-07-28
ZA201401954B (en) 2016-06-29
PL2758061T3 (pl) 2017-08-31
IL231489A (en) 2017-01-31
KR101987512B1 (ko) 2019-06-10
ES2614923T3 (es) 2017-06-02
US9901638B2 (en) 2018-02-27
EP2758061B1 (en) 2016-11-16
AU2012311235B2 (en) 2017-02-02
CN103813797B (zh) 2017-07-11
JP2014526548A (ja) 2014-10-06
RU2014115807A (ru) 2015-10-27
RU2621129C2 (ru) 2017-05-31
IL231489A0 (en) 2014-04-30
EP2758061A2 (en) 2014-07-30
CA2849255C (en) 2019-06-04

Similar Documents

Publication Publication Date Title
BR112014006473A2 (pt) composição e método para tratamento de uma doença autoimune
BR112015028879A2 (pt) derivados heterocíclicos
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
EA201892339A3 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
GEP20166438B (en) Imidazopyrrolidinone compounds
EA201290919A1 (ru) Индазольные соединения и их применение
MX2012004525A (es) Compuestos.
EA201001639A1 (ru) Композиции и способы их получения и применения
AR101740A1 (es) Terapia de combinación y composiciones
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
MX2011008899A (es) Nuevas orto-aminoamidas para el tratamiento del cancer.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX358598B (es) Partículas inmuno-moduladoras modificadas.
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
BR112015019919A2 (pt) compostos bicíclicos
BR112013026680A2 (pt) composto, método de tratamento de uma doença inflamatória e composição farmacêutica
BR112012008310A2 (pt) métodos para tratamento de tumores cerebrais
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MD4629B1 (ro) Metode de tratament a fibrozei şi cancerului
BR112017007916A2 (pt) compostos sarms para tratamento de distúrbios urológicos
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
EA201491581A1 (ru) Везикулярные композиции

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]